Galapagos is looking for a fresh start after a rough few years. The Belgian biotech has outlined plans to branch off into two ...

Novo Nordisk is doubling down on its computational biotech partner Valo Health, expanding their collaboration from 11 ...

Maze Therapeutics has submitted its pitch for an initial public offering after disclosing a $115 million Series D, forging a ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

Aet­na is go­ing af­ter an­oth­er phar­ma­ceu­ti­cal com­pa­ny for al­leged price fix­ing. The health in­sur­ance provider ...

New an­ti-obe­si­ty drugs should meet a min­i­mum lev­el of weight loss to be con­sid­ered for ap­proval, the FDA said ...

Bayer’s Nexavar and Boehringer Ingelheim's Spiriva are among a handful of drugs with reduced US list prices for the new year, ...

Immuneering's MEK inhibitor IMM-1-104 shows positive Phase 2a results in pancreatic cancer with 43% response rate when ...

Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...

This year's first radiopharmaceutical deal is slated to expand BWX Technologies’ presence in the North American nuclear tech ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for ...

XyloCor raises $67.5M Series B led by Jeito Capital for XC001 gene therapy trials in cardiac patients. CEO Al Gianchetti says ...